IRIS
PIERANTOZZI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.417
EU - Europa 5.181
AS - Asia 1.605
Continente sconosciuto - Info sul continente non disponibili 22
SA - Sud America 21
OC - Oceania 8
AF - Africa 3
Totale 55.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.388
IT - Italia 2.110
SG - Singapore 984
UA - Ucraina 633
DE - Germania 570
IE - Irlanda 516
CN - Cina 402
FR - Francia 312
RU - Federazione Russa 303
GB - Regno Unito 189
FI - Finlandia 148
KR - Corea 137
SE - Svezia 126
PL - Polonia 118
NL - Olanda 42
BE - Belgio 29
CA - Canada 26
EU - Europa 21
GR - Grecia 15
IN - India 15
JP - Giappone 15
CZ - Repubblica Ceca 14
VN - Vietnam 14
BR - Brasile 12
RO - Romania 12
CH - Svizzera 10
KG - Kirghizistan 8
AU - Australia 7
CL - Cile 5
ES - Italia 5
HK - Hong Kong 5
PT - Portogallo 5
TR - Turchia 5
UZ - Uzbekistan 5
AL - Albania 4
AT - Austria 4
SK - Slovacchia (Repubblica Slovacca) 4
DK - Danimarca 3
IL - Israele 3
AZ - Azerbaigian 2
DM - Dominica 2
EG - Egitto 2
IQ - Iraq 2
LU - Lussemburgo 2
MY - Malesia 2
PE - Perù 2
SM - San Marino 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BY - Bielorussia 1
CO - Colombia 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 55.257
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.874
Wilmington 13.213
Houston 12.126
Fairfield 1.767
Ann Arbor 1.083
Singapore 877
Ashburn 800
Seattle 623
Cambridge 608
Chandler 607
Jacksonville 577
Dublin 478
Medford 365
Rome 294
Santa Clara 241
Dearborn 230
Milan 187
Beijing 185
Lawrence 169
New York 123
Kraków 111
San Diego 97
Menlo Park 70
Moscow 68
Verona 46
London 44
Turin 42
Norwalk 39
Mülheim 36
Zhengzhou 36
Durham 35
Falls Church 33
Naples 33
Redwood City 32
Florence 31
Brussels 28
Shanghai 28
Council Bluffs 27
Helsinki 27
Munich 27
Mountain View 24
Palo Alto 24
Genoa 23
Sassari 22
Bologna 20
Nanjing 20
San Jose 20
Seoul 20
Boardman 19
University Park 19
Padova 18
St Louis 18
Hefei 17
Toronto 17
Kunming 16
Bolzano 15
Phoenix 15
Brno 13
Catania 13
Nürnberg 13
Los Angeles 12
Modena 12
Reggio Calabria 12
Bari 11
Bergamo 11
Palermo 11
Pisa 11
Redmond 11
Saint Petersburg 11
Trento 11
Engelhard 10
Garden City 10
Hounslow 10
Kilburn 10
Mcallen 10
Pavia 10
Athens 9
Creede 9
Parma 9
Wuhan 9
Brescia 8
Del Norte 8
Dong Ket 8
Frankfurt am Main 8
Nuremberg 8
Reggio Emilia 8
Chengdu 7
Pune 7
Ravenna 7
The Dalles 7
Altamura 6
Cagliari 6
Caserta 6
Changsha 6
Detroit 6
Guangzhou 6
Islington 6
Jinan 6
Messina 6
Partinico 6
Totale 50.028
Salva come PNG Salva come JPEG
Nome #
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT) 1.635
malattia di alzheimer e altre demenze diagnosi e terapia integrata. 711
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 441
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 441
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 441
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 435
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 433
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 431
Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study 430
SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status 427
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 425
Electrophysiological evidence for visuocognitive dysfunction in younger non Caucasian patients with Parkinson's disease 425
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease 424
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients 424
123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study 424
Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes 420
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 420
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 418
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 418
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 416
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients 415
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease 413
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 410
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 409
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 409
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 407
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 407
Optic Nerve dysfunction in obstructive sleep apnea: An electrophysiological study 407
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome 404
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 403
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 402
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 402
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study 401
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 400
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 398
Therapy for dyskinesias in Parkinson’s disease patients 397
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 396
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 396
Restless legs syndrome and poliomyelitis: New evidences of an old observation? 396
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 394
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 392
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease 391
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials 391
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 391
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 390
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 390
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 390
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 389
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 388
Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: An effective tool to investigate in vivo GABAergic cortical inhibition in humans 383
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations 382
Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity 382
Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy 380
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 379
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study 379
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients - An ambulatory polysomnographic study 378
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 378
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 377
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms 372
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 369
Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography 368
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 367
Catecholamine-based treatment in AD patients: expectations and delusions 366
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 365
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 364
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 364
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 364
Alexithymia is a non-motor symptom of Parkinson disease 363
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss? 363
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease 360
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 360
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 358
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 357
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 355
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 355
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 353
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 353
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study 353
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 352
Long term effects of Helicobacter pylori eradication on L-dopa absorption in Parkinson's disease 352
Neurological complications of pregnancy 352
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 350
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study 350
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 348
Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? 344
P3 components evoked by unilateral and bilateral somatosensory stimulation: normative data for the study of neglect syndrome 344
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 343
Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram 343
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 341
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 339
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 339
Deep brain stimulation (DBS) attentional effects parallel those of l-dopa treatment 338
Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease? 333
Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients 333
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD 330
When cognitive decline and depression coexist in the elderly: CSF biomarkers analysis can differentiate Alzheimer's disease from late-life depression 330
Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients 328
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 328
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 327
Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: A pilot study 326
Totale 39.734
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.988
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.988
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209.727 0 0 0 0 1.225 1.511 1.212 1.309 1.310 1.196 857 1.107
2020/20218.487 985 1.094 958 1.071 837 880 1.041 782 214 170 371 84
2021/20222.000 64 249 99 74 69 131 319 90 116 133 149 507
2022/20231.951 211 130 71 211 142 467 183 106 152 36 146 96
2023/20241.722 126 57 113 105 151 205 147 256 69 136 104 253
2024/20252.645 221 1.148 618 463 195 0 0 0 0 0 0 0
Totale 56.081